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complications. Orlistat, a drug for achieving and main-
taining weight loss, reduces cardiovascular risk factors in
randomized clinical trials. The objectives of this study
were to estimate the resulting long-term clinical conse-
quences and cost-effectiveness of treating obese type 2 di-
abetic patients with orlistat.
METHODS: A Markov model was developed to predict,
over a 10-year period, the complication rates and mortal-
ity with and without a two-year orlistat treatment, as-
suming a five-year weight catch-up period after treatment
according to epidemiological evidence. A stepwise ap-
proach was used to apply published clinical data into pre-
diction of long-term outcome. As a first step, the impact
of orlistat on HbA1c, blood pressure and cholesterol was
obtained. In a second step, the impact of decreasing these
risk factors on mortality and micro- and macrovascular
complications was obtained. Four subgroups, defined by
the presence of arterial hypertension and/or hypercholes-
terolemia, were studied.
RESULTS: Cost-effectiveness varies between 3,462 Euro/
life year gained (LYG) for obese diabetic patients with hy-
pertension and hypercholesterolemia, and 19,986 Euro/
LYG for obese diabetic patients without other risk fac-
tors. Sensitivity analyses on all relevant variables indicate
that these results are very robust.
CONCLUSIONS: Our results suggest that orlistat is cost-
effective in the management of obese type 2 diabetic pa-
tients, especially in those with concomitant hypercholes-
terolemia and/or hypertension.
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OBJECTIVE: Despite the existence of effective therapy,
millions of Europeans have blood pressure (BP) above in-
ternationally agreed targets for control of cardiovascular
risk. There is particular resistance to aggressive manage-
ment of the elderly. We estimated the acute health-care
costs resulting from failure to achieve BP targets in older
adults in France, Germany, Italy, Sweden and the UK.
METHODS: We constructed a burden of disease model
to estimate the costs of uncontrolled hypertension in this
group. Prevalence of uncontrolled hypertension was
taken from the MONICA study and published surveys.
The relationships between three cardiovascular (CV)
events (symptomatic acute myocardial infarction (AMI),
congestive heart failure (CHF) and stroke) and BP were
estimated from a large prospective study (the HOT trial).
Costs came from government sources and published stud-
ies. We estimated the acute medical costs of these events
at current prevalence of uncontrolled hypertension and
expected number of events and cost if BP were treated to
target levels. Stochastic simulation was used to construct
confidence intervals.
RESULTS: Among adults older than 65 years in the five
countries, an estimated 15.2m have BP above 160/95
mmHg and a further 12.9m have BP in the range 140/90–
160/95 mmHg. The model estimated that 505,000 CV
events (AMI–91,000; CHF–190,000, stroke–224,000)
occur each year in those older than 65 in these countries,
resulting in annual acute hospital costs of Euro2.3Bn
(95% CI Euro2.04–2.53Bn). One hundred twenty eight
thousand of these events (AMI–9,000; CHF–55,000,
stroke–64,000) could be avoided if BP targets were met.
The annual cost of these avoidable events was estimated
to be Euro560m (95% CI Euro300–783m), representing
24.2% of the acute medical cost of these CV events in
this population.
CONCLUSION: Failing to implement existing guidelines
for BP management in the elderly contributes substan-
tially to the total human and economic burden of CV dis-
ease.
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OBJECTIVE: The reliable and valid capture of patient-
reported outcomes (PROs) are becoming increasingly im-
portant endpoints for the pharmaceutical industry. PROs
are data reported by the patient, and can include health-
related quality of life, functional status, symptoms, pain,
bother, satisfaction, work loss, reduced productivity, and
the use of medical resources. These data, when included
in studies, have traditionally been collected using paper-
based methods. Technological advances in electronic
data capture, such as handheld computers, internet-based
solutions, and interactive voice-response systems, facili-
tate collecting PROs and are important new tools for
clinical and outcomes researchers. Our objective was to
examine compliance rates between a handheld computer
diary system and a paper-based diary.
METHODS: Eighty pain patients were randomly as-
signed to complete a three-week, diary-monitoring proto-
col using either a compliance-enhanced electronic diary
system or a paper diary. The paper diary was covertly in-
strumented to allow for objective determination of when
the diary was opened or closed.
RESULTS: Participants submitted diary cards corre-
sponding to 89% of assigned assessment times (15
min). However, the electronic record indicated that ac-
tual compliance with the paper diary was only 11%, indi-
cating a high level of faked compliance. On 32% of all
study days the paper diary was not opened, yet reported
410 Abstracts
compliance for these days exceeded 90%. Evidence for
back and forward filling of paper diary cards was ob-
served. For the compliance-enhanced electronic diary, the
actual compliance rate was 93%.
CONCLUSIONS: Data from paper-based diaries are of
questionable validity, given that many of their entries are
not completed as required by the protocol. Science-based
electronic diaries can produce high rates of patient com-
pliance in the field. Improved methods for data collection
should encourage researchers in the pharmaceutical in-
dustry to aggressively evaluate electronic PRO (ePRO)
data to help differentiate their products.
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OBJECTIVE: Increasingly, federal authorities are request-
ing power calculations for secondary endpoints in clinical
trials, including patient reported outcomes (PRO). How-
ever, most PRO measures do not provide power calcula-
tions in their manuals; if provided, they are often based on
mixed samples of males and females. It is well docu-
mented that female and male PRO scores often differ.
Thus when designing women’s health trials, it may be
worthwhile to conduct power calculations using women’s
PRO scores and standard deviations. This study presents
the power and sample-size calculations for a variety of
questionnaires used in women’s health studies.
METHODS: The Menopause Quality of Life question-
naire (MENQOL), Women’s Health Questionnaire (WHQ),
Psychological General Well-Being Index (PGWB), and
Short Form 36 and 12 (SF-36/SF-12) were assessed. Pub-
lished information on scores and standard deviations in
female populations were used to determine sample sizes
needed to detect differences between two experimental
groups, post-intervention.
RESULTS: Results varied by questionnaire, due in part to
varying score ranges across questionnaires. For example, to
achieve 90% power with a ten-point difference the follow-
ing sample sizes per treatment arm were required: 158
women when using the MENQOL vasomotor score (range:
0–100); 47 women when using the WHQ total score (range:
0–102); 70 women when using the PGWB total score
(range: 22–132); 24 and 21 women when using the SF-36
and SF-12 Physical Component Summary (no floor/ceiling).
CONCLUSION: When calculating sample sizes, it is nec-
essary to keep in mind the questionnaire’s possible score
range in order to ensure that the power calculation is
based on a clinically meaningful difference between treat-
ment groups. These results may be used to help calculate
sample sizes needed to achieve sufficient power to detect
statistically significant differences in women’s health tri-
als for these widely used measures.
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OBJECTIVES: The availability of reliable methods for im-
puting hospital costs (e.g., relative values from the U.S. diag-
nosis-related group (DRG) payment system, cost weights
and average length of stay (LOS) estimates from the Austra-
lian refined DRG system, or average LOS from the French
Patient Homogeneous Groups), allows one to address two
design questions related to the collection of hospital unit
cost data for use in multinational clinical trials with eco-
nomic endpoints: 1) In individual countries, for how many
types of hospitalization should estimates be obtained? 2)
For how many countries should they be obtained?
METHODS: We addressed these questions by assuming
that unit cost estimates for 47 types of hospitalization
collected in four western European countries represented
the universe of hospitalizations. This assumption pro-
vided a population estimate against which we could mea-
sure the error associated with imputations in samples
drawn from the population. To answer the first question,
we: 1) randomly sampled subsets of hospitalization types
from this population and used them to develop imputa-
tion regressions; 2) used the results of the regressions to
impute costs from the remaining hospitalization types,
and 3) estimated measures of imputation error within
each sample. To answer the second question, we per-
formed a similar analysis, but instead sampled countries.
RESULTS: We found that the imputation error decreased
as the number of types of hospitalization and countries
sampled increased, but that the rate of reduction in error
shrank. We also found that error was minimized by ob-
taining estimates for fewer types of hospitalization from
more countries than the reverse.
CONCLUSION: The availability of reliable methods for
imputing hospitalization costs allows one to economize
on data collection. Our experiment suggested that col-
lecting a small number of estimates (in our data, approxi-
mately 25) in as many countries as is feasible minimizes
imputation error.
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